5. Business Combinations Acquisitions On July 2, 2019, we acquired the Pinnacle and Diabetes Collaborative Registries from the American College of Cardiology (ACC) as part of our broader strategic partnership with the ACC. The total purchase price was $19.7 million, consisting of an initial payment of $11.7 million plus up to an aggregate of $8.0 million pending the attainment certain milestones over the next 18 months. The contingent consideration of up to $8.0 million was valued at $5.0 million at the time of closing. As part of this partnership, we operate Pinnacle and Diabetes Collaborative Registries, which extends our EHR-enabled ambulatory network to create a large-scale chronic disease network. The business is included in our Data, Analytics and Care Coordination business segment. On June 10, 2019, we acquired the assets of a business engaged in the development, implementation, customization, marketing, licensing and sale of a specialty prescription drug platform, including software that collects, saves and transmits information required to fill a prescription. The drug platform and software enables healthcare providers, pharmacists and payors to digitally interact with one another to fill a prescription. The business is included in our Data, Analytics and Care Coordination business segment. On March 1, 2019, we acquired all of the outstanding minority interests in Pulse8, Inc., a healthcare analytics and technology company that provides business intelligence software solutions for health plans and at-risk providers to enable them to analyze their risk adjustment and quality management programs, for $53.8 million (subject to adjustments for net working capital and a contingency holdback). We initially acquired a controlling stake in Pulse 8, Inc. on September 8, 2016. This transaction was treated as an equity transaction, and the cash payment is reported as part of cash flow from financing activities in the consolidated statement of cash flows for the nine months ended September 30, 2019. Divestitures On July 30, 2020, we signed an asset purchase agreement with Strata Decision Technology LLC, an Illinois limited liability company (Strata), and Roper Technologies, Inc., a Delaware corporation (the EPSi Purchase Agreement), pursuant to which Strata has agreed to purchase substantially all of the assets of our EPSi TM business for $365.0 million, subject to adjustment upon the terms and conditions set forth in the EPSi Purchase Agreement. The transactions contemplated by the EPSi Purchase Agreement are subject to customary closing conditions, including the applicable waiting period (and any extensions thereof) under the Hart-Scott-Rodino Antitrust Improvements Act having expired or otherwise having been terminated. As of September 30, 2020, the assets and liabilities related to the EPSi Purchase Agreement were classified as held-for-sale on our consolidated balance sheet. The held-for-sale assets and liabilities are classified as current since we expect to complete the sale of the disposal group within the next 12 months. The business classified as held-for-sale was classified in continuing operations as the disposition does not represent a strategic shift that will have a major effect on our operations and financial results. On October 15, 2020, we completed the sale of the EPSi TM business, which is further discussed in Note 17 Subsequent Events. The following table provides the components of those assets and liabilities related to the EPSi Purchase Agreement which are classified as held-for-sale as of September 30, 2020: (In thousands) September 30, 2020 Assets held for sale: Current assets: Accounts receivable, net of allowance of $416 $ 10,088 Contract assets 4,147 Prepaid expenses and other current assets 956 Total current assets classified as held for sale 15,191 Fixed assets, net 254 Software development costs, net 10,977 Goodwill 74,663 Contract assets - long-term 2,765 Right-of-use assets - operating leases 932 Total assets held for sale $ 104,782 Liabilities related to assets held for sale: Current liabilities: Accrued expenses $ 964 Accrued compensation and benefits 1,714 Deferred revenue 13,400 Current operating lease liabilities 371 Total current liabilities classified as held for sale 16,449 Deferred revenue 429 Long-term operating lease liabilities 601 Total liabilities related to assets held for sale $ 17,479